Diane M. Citron

Diane M. Citron's AcademicInfluence.com Rankings

Diane M. Citron

Biology

#11639

World Rank

#15049

Historical Rank

Microbiology

#667

World Rank

#736

Historical Rank

biology Degrees

Download Badge

Biology

Why Is Diane M. Citron Influential?

(Suggest an Edit or Addition)

(See a Problem?)

Diane M. Citron's Published Works

Number of citations in a given year to any of this author's works

Total number of citations to an author for the works they published in a given year. This highlights publication of the most important work(s) by the author

Published Works

Wadsworth Anaerobic Bacteriology Manual (1980) (1201)
Bacteriologic analysis of infected dog and cat bites. Emergency Medicine Animal Bite Infection Study Group. (1999) (757)
Selective and differential medium for isolation of Clostridium difficile (1979) (640)
Bacteriology of Moderate-to-Severe Diabetic Foot Infections and In Vitro Activity of Antimicrobial Agents (2007) (439)
Reclassification of Clostridium difficile as Clostridioides difficile (Hall and O'Toole 1935) Prévot 1938. (2016) (423)
Methods for antimicrobial susceptibility testing of anaerobic bacteria. Approved standard M11-A7 2007 (2012) (278)
Ertapenem versus piperacillin/tazobactam for diabetic foot infections (SIDESTEP): prospective, randomised, controlled, double-blinded, multicentre trial (2005) (258)
Effects of control interventions on Clostridium difficile infection in England: an observational study (2017) (252)
Evaluation of the E test for susceptibility testing of anaerobic bacteria (1991) (222)
Bacteriology of human and animal bite wounds (1978) (215)
Suppression of gastric acid secretion in patients with gastroesophageal reflux disease results in gastric bacterial overgrowth and deconjugation of bile acids (2007) (208)
Lactobacillus species: taxonomic complexity and controversial susceptibilities. (2015) (204)
Diabetic Foot Infections: Bacteriology and activity of 10 oral antimicrobial agents against bacteria isolated from consecutive cases (1996) (182)
Clinical presentation and bacteriologic analysis of infected human bites in patients presenting to emergency departments. (2003) (149)
Relapse Versus Reinfection: Recurrent Clostridium difficile Infection Following Treatment With Fidaxomicin or Vancomycin (2012) (139)
A central role for venom in predation by Varanus komodoensis (Komodo Dragon) and the extinct giant Varanus (Megalania) priscus (2009) (117)
Desulfovibrio desulfuricans Bacteremia and Review of Human Desulfovibrio Infections (2003) (115)
Update on the taxonomy and clinical aspects of the genus fusobacterium. (2002) (109)
In Vitro Activities of Dalbavancin and Nine Comparator Agents against Anaerobic Gram-Positive Species and Corynebacteria (2003) (99)
Comparative Susceptibilities to Fidaxomicin (OPT-80) of Isolates Collected at Baseline, Recurrence, and Failure from Patients in Two Phase III Trials of Fidaxomicin against Clostridium difficile Infection (2011) (97)
In Vitro Activities of the New Semisynthetic Glycopeptide Telavancin (TD-6424), Vancomycin, Daptomycin, Linezolid, and Four Comparator Agents against Anaerobic Gram-Positive Species and Corynebacterium spp (2004) (96)
In Vitro Activities of Ramoplanin, Teicoplanin, Vancomycin, Linezolid, Bacitracin, and Four Other Antimicrobials against Intestinal Anaerobic Bacteria (2003) (94)
Bacteriology of rattlesnake venom and implications for therapy. (1979) (90)
In Vitro Activities of Nontraditional Antimicrobials against Multiresistant Acinetobacter baumannii Strains Isolated in an Intensive Care Unit Outbreak (2000) (90)
Pharmacokinetics and Pharmacodynamics of Linezolid in Obese Patients with Cellulitis (2005) (88)
Periodontal Bacteria in Rabbit Mandibular and Maxillary Abscesses (2002) (84)
In Vitro Activities of Daptomycin, Vancomycin, Quinupristin- Dalfopristin, Linezolid, and Five Other Antimicrobials against 307 Gram-Positive Anaerobic and 31 Corynebacterium Clinical Isolates (2003) (84)
Comparative In Vitro Activities of Ertapenem (MK-0826) against 1,001 Anaerobes Isolated from Human Intra-Abdominal Infections (2000) (83)
Gram-negative anaerobic bacilli: Their role in infection and patterns of susceptibility to antimicrobial agents. II. Little-known Fusobacterium species and miscellaneous genera. (1981) (83)
Antimicrobial Activities of Fidaxomicin (2012) (83)
Biochemical Differentiation and Comparison of Desulfovibrio Species and Other Phenotypically Similar Genera (2005) (80)
Role of anaerobic bacteria in bite-wound infections. (1984) (79)
Dog bite wounds and infection: a prospective clinical study. (1980) (76)
Linezolid Activity Compared to Those of Selected Macrolides and Other Agents against Aerobic and Anaerobic Pathogens Isolated from Soft Tissue Bite Infections in Humans (1999) (76)
Jonquetella anthropi gen. nov., sp. nov., the first member of the candidate phylum 'Synergistetes' isolated from man. (2007) (75)
Identification and antimicrobial resistance patterns of clinical isolates of Clostridium clostridioforme, Clostridium innocuum, and Clostridium ramosum compared with those of clinical isolates of Clostridium perfringens (1995) (75)
Comparative activity of ciprofloxacin, ofloxacin, sparfloxacin, temafloxacin, CI-960, CI-990, and WIN 57273 against anaerobic bacteria (1992) (71)
Multi-drug resistant Bacteroides fragilis recovered from blood and severe leg wounds caused by an improvised explosive device (IED) in Afghanistan. (2011) (70)
In Vitro Activity of Ceftobiprole against Aerobic and Anaerobic Strains Isolated from Diabetic Foot Infections (2006) (70)
Comparative In Vitro Activities of SMT19969, a New Antimicrobial Agent, against Clostridium difficile and 350 Gram-Positive and Gram-Negative Aerobic and Anaerobic Intestinal Flora Isolates (2013) (69)
Brain abscess and cerebritis. (1984) (69)
Comparative In Vitro Activities of GAR-936 against Aerobic and Anaerobic Animal and Human Bite Wound Pathogens (2000) (69)
16S-23S rDNA internal transcribed spacer sequences for analysis of the phylogenetic relationships among species of the genus Fusobacterium. (2002) (68)
National hospital survey of anaerobic culture and susceptibility methods: III. (2008) (68)
Gram-negative anaerobic bacilli: their role in infection and patterns of susceptibility to antimicrobial agents. I. Little-known Bacteroides species. (1980) (67)
In Vitro Activities of Dalbavancin and 12 Other Agents against 329 Aerobic and Anaerobic Gram-Positive Isolates Recovered from Diabetic Foot Infections (2006) (65)
In Vitro Activity of Moxifloxacin against 923 Anaerobes Isolated from Human Intra-Abdominal Infections (2006) (65)
Two Novel Vaginal Microbicides (Polystyrene Sulfonate and Cellulose Sulfate) Inhibit Gardnerella vaginalis and Anaerobes Commonly Associated with Bacterial Vaginosis (2002) (61)
Detection, identification, and comparison of Capnocytophaga, Bacteroides ochraceus, and DF-1 (1979) (61)
Impact of an intervention to control Clostridium difficile infection on hospital- and community-onset disease; an interrupted time series analysis. (2010) (60)
In vitro activity of Bay 12-8039, a new 8-methoxyquinolone, compared to the activities of 11 other oral antimicrobial agents against 390 aerobic and anaerobic bacteria isolated from human and animal bite wound skin and soft tissue infections in humans (1997) (60)
Synergistes Group Organisms of Human Origin (2006) (57)
Comparative In Vitro Activities of LFF571 against Clostridium difficile and 630 Other Intestinal Strains of Aerobic and Anaerobic Bacteria (2012) (56)
Antibacterial activity of crotalid venoms against oral snake flora and other clinical bacteria. (1991) (56)
Lack of in vitro efficacy of oral forms of certain cephalosporins, erythromycin, and oxacillin against Pasteurella multocida (1988) (56)
In Vitro Activities of CB-183,315, Vancomycin, and Metronidazole against 556 Strains of Clostridium difficile, 445 Other Intestinal Anaerobes, and 56 Enterobacteriaceae Species (2011) (56)
Bacteriology of a Bear Bite Wound to a Human: Case Report (2004) (56)
Comparative activities of cefuroxime, amoxicillin-clavulanic acid, ciprofloxacin, enoxacin, and ofloxacin against aerobic and anaerobic bacteria isolated from bite wounds (1988) (55)
Effect of oxygen limitation on the in vitro activity of levofloxacin and other antibiotics administered by the aerosol route against Pseudomonas aeruginosa from cystic fibrosis patients. (2010) (54)
Activity of Gatifloxacin Compared to Those of Five Other Quinolones versus Aerobic and Anaerobic Isolates from Skin and Soft Tissue Samples of Human and Animal Bite Wound Infections (1999) (54)
Impact of cefoperazone therapy on fecal flora (1982) (54)
In Vitro Activity of Gemifloxacin (SB 265805) against Anaerobes (1999) (53)
Comparative in vitro activity of ertapenem and 11 other antimicrobial agents against aerobic and anaerobic pathogens isolated from skin and soft tissue animal and human bite wound infections. (2001) (53)
Clostridium aldenense sp. nov. and Clostridium citroniae sp. nov. Isolated from Human Clinical Infections (2006) (53)
Immunoblots, antimicrobial resistance, and bacteriophage typing of oxacillin-resistant Staphylococcus aureus (1988) (52)
Annual incidence, epidemiology, and comparative in vitro susceptibilities to cefoxitin, cefotetan, cefmetazole, and ceftizoxime of recent community-acquired isolates of the Bacteroides fragilis group (1988) (51)
In Vitro Activities of Daptomycin, Vancomycin, and Penicillin against Clostridium difficile, C. perfringens, Finegoldia magna, and Propionibacterium acnes (2006) (51)
Comparative In Vitro Susceptibilities of 396 Unusual Anaerobic Strains to Tigecycline and Eight Other Antimicrobial Agents (2006) (50)
Alterations in human fecal flora, including ingrowth of Clostridium difficile, related to cefoxitin therapy (1984) (50)
Typing and susceptibility of bacterial isolates from the fidaxomicin (OPT-80) phase II study for C. difficile infection. (2009) (49)
Failure of rapid agglutination methods to detect oxacillin-resistant Staphylococcus aureus (1986) (49)
Introduction of Ertapenem into a Hospital Formulary: Effect on Antimicrobial Usage and Improved In Vitro Susceptibility of Pseudomonas aeruginosa (2009) (49)
Description of two novel members of the family Erysipelotrichaceae: Ileibacterium valens gen. nov., sp. nov. and Dubosiella newyorkensis, gen. nov., sp. nov., from the murine intestine, and emendation to the description of Faecalibaculum rodentium. (2017) (48)
Comparative activity of the quinolones against anaerobic bacteria isolated at community hospitals (1985) (46)
Anaerobic bacteria cultured from the tongue dorsum of subjects with oral malodor. (2003) (46)
Characterization of saccharolytic Bacteroides and Prevotella isolates from infected dog and cat bite wounds in humans (1997) (46)
Novel Bacterium Isolated from a Lung Transplant Patient with Cystic Fibrosis (1999) (46)
Resistance Trends in Antimicrobial Susceptibility of Anaerobic Bacteria, Part I (2011) (45)
In Vitro Activity of Ceftaroline against 623 Diverse Strains of Anaerobic Bacteria (2010) (44)
Comparative in vitro activities of dalbavancin and seven comparator agents against 41 Staphylococcus species cultured from osteomyelitis infections and 18 VISA and hVISA strains. (2014) (44)
In Vitro Activities of Doripenem and Six Comparator Drugs against 423 Aerobic and Anaerobic Bacterial Isolates from Infected Diabetic Foot Wounds (2007) (44)
Activities of Telithromycin (HMR 3647, RU 66647) Compared to Those of Erythromycin, Azithromycin, Clarithromycin, Roxithromycin, and Other Antimicrobial Agents against Unusual Anaerobes (1999) (43)
In Vitro Activity of Biapenem plus RPX7009, a Carbapenem Combined with a Serine β-Lactamase Inhibitor, against Anaerobic Bacteria (2013) (42)
Changes in the antibiotic susceptibility of anaerobic bacteria from 2007-2009 to 2010-2012 based on the CLSI methodology. (2016) (41)
Comparative susceptibility of the Bacteroides fragilis group species and other anaerobic bacteria to meropenem, imipenem, piperacillin, cefoxitin, ampicillin/sulbactam, clindamycin and metronidazole. (1993) (41)
Comparative In Vitro Activities of XRP 2868, Pristinamycin, Quinupristin-Dalfopristin, Vancomycin, Daptomycin, Linezolid, Clarithromycin, Telithromycin, Clindamycin, and Ampicillin against Anaerobic Gram-Positive Species, Actinomycetes, and Lactobacilli (2005) (40)
Pelvic Abscess Due to Ochrobactrum anthropi in an Immunocompetent Host: Case Report and Review of the Literature (2006) (40)
In Vitro Activities of Daptomycin, Ciprofloxacin, and Other Antimicrobial Agents against the Cells and Spores of Clinical Isolates of Bacillus Species (2006) (40)
Characterization of a β-lactamase from Clostridium clostridioforme (1994) (39)
In Vitro Activity of Ceftazidime-NXL104 against 396 Strains of β-Lactamase-Producing Anaerobes (2011) (39)
Clinical efficacy and correlation of clinical outcomes with in vitro susceptibility for anaerobic bacteria in patients with complicated intra-abdominal infections treated with moxifloxacin. (2011) (39)
Efficacy of vancomycin and daptomycin against Staphylococcus aureus isolates collected over 29 years. (2010) (39)
National hospital survey of anaerobic culture and susceptibility testing methods: results and recommendations for improvement (1992) (39)
Susceptibility of bite wound bacteria to seven oral antimicrobial agents, including RU-985, a new erythromycin: considerations in choosing empiric therapy (1986) (39)
Frequency of isolation of Porphyromonas species from infected dog and cat bite wounds in humans and their characterization by biochemical tests and arbitrarily primed-polymerase chain reaction fingerprinting. (1996) (38)
Development of Tyrocidine A analogues with improved antibacterial activity. (2007) (38)
Comparative in vitro activities of trovafloxacin (CP-99,219) against 221 aerobic and 217 anaerobic bacteria isolated from patients with intra-abdominal infections (1997) (38)
Pelvic Abscess Due to Ochrobactrum anthropi in an Immunocompetent Host: Case Report and Review of the Literature (2006) (37)
Comparative in vitro activities of azithromycin, Bay y 3118, levofloxacin, sparfloxacin, and 11 other oral antimicrobial agents against 194 aerobic and anaerobic bite wound isolates (1995) (37)
In Vitro Activities of Garenoxacin (BMS 284756) against 108 Clinical Isolates of Gardnerella vaginalis (2002) (37)
Comparative in vitro activity of REP3123 against Clostridium difficile and other anaerobic intestinal bacteria. (2009) (36)
Fatal sepsis due to a beta-lactamase-producing strain of Fusobacterium nucleatum subspecies polymorphum. (1995) (36)
Ridinilazole: a novel therapy for Clostridium difficile infection. (2016) (36)
Fusobacterium canifelinum sp. nov., from the oral cavity of cats and dogs. (2004) (35)
Predictors of death after Clostridium difficile infection: a report on 128 strain-typed cases from a teaching hospital in the United Kingdom. (2010) (35)
Comparison of the inoculum effects of members of the family Enterobacteriaceae on cefoxitin and other cephalosporins, beta-lactamase inhibitor combinations, and the penicillin-derived components of these combinations (1991) (34)
A selective medium for Fusobacterium spp. (1991) (34)
In vitro activity of azithromycin and nine comparator agents against 296 strains of oral anaerobes and 31 strains of Eikenella corrodens. (2006) (33)
Serious infection with Leptotrichia buccalis. Report of a case and review of the literature. (1980) (33)
Potential of topical norfloxacin therapy. Comparative in vitro activity against clinical ocular bacterial isolates. (1987) (32)
Evaluation of the RapID CB Plus System for Identification of Corynebacterium Species and Other Gram-Positive Rods (1998) (32)
Pasteurellamultocida subsp.multocida and P. multocida subsp.septica Differentiation by PCR Fingerprinting and α-Glucosidase Activity (2001) (32)
Comparative In Vitro Activities of ABT-773 against Aerobic and Anaerobic Pathogens Isolated from Skin and Soft-Tissue Animal and Human Bite Wound Infections (2000) (32)
General microbiology and in vitro susceptibility of anaerobes isolated from complicated skin and skin-structure infections in patients enrolled in a comparative trial of ertapenem versus piperacillin-tazobactam. (2002) (32)
Activities of Gemifloxacin (SB 265805, LB20304) Compared to Those of Other Oral Antimicrobial Agents against Unusual Anaerobes (1999) (32)
Comparative in vitro activity of faropenem and 11 other antimicrobial agents against 405 aerobic and anaerobic pathogens isolated from skin and soft tissue infections from animal and human bites. (2002) (31)
Infection after elective colorectal surgery: bacteriological analysis of failures in a randomized trial of cefotetan vs. ertapenem prophylaxis. (2009) (31)
In vitro activity of oritavancin (LY333328), vancomycin, clindamycin, and metronidazole against Clostridium perfringens, Propionibacterium acnes, and anaerobic Gram-positive cocci. (2005) (30)
Simian bites and bacterial infection. (1995) (30)
Bacteriology of human bite wound infections. (2003) (30)
Peptoniphilus coxii sp. nov. and Peptoniphilus tyrrelliae sp. nov. isolated from human clinical infections. (2012) (30)
Trovafloxacin compared with levofloxacin, ofloxacin, ciprofloxacin, azithromycin and clarithromycin against unusual aerobic and anaerobic human and animal bite-wound pathogens. (1998) (30)
In Vitro Activities of the Des-Fluoro(6) Quinolone BMS-284756 against Aerobic and Anaerobic Pathogens Isolated from Skin and Soft Tissue Animal and Human Bite Wound Infections (2002) (29)
In vitro activities of tinidazole and metronidazole against Clostridium difficile, Prevotella bivia and Bacteroides fragilis. (2005) (29)
Survival of Aerobic and Anaerobic Bacteria in Purulent Clinical Specimens Maintained in the Copan Venturi Transystem and Becton Dickinson Port-a-Cul Transport Systems (2000) (28)
How far should a clinical laboratory go in identifying anaerobic isolates, and who should pay? (1993) (28)
Recovery of an unusual Flavobacterium group IIb-like isolate from a hand infection following pig bite (1990) (28)
Ciprofloxacin versus cinoxacin in therapy of urinary tract infections. A randomized, double-blind trial. (1987) (28)
Comparative In Vitro Activities of Retapamulin (SB-275833) against 141 Clinical Isolates of Propionibacterium spp., Including 117 P. acnes Isolates (2006) (28)
Susceptibility of Eikenella corrodens to newer and older quinolones (1986) (27)
Susceptibility of Eikenella corrodens to penicillin, apalcillin, and twelve new cephalosporins (1984) (27)
Comparative In Vitro Activities of SMT19969, a New Antimicrobial Agent, against 162 Strains from 35 Less Frequently Recovered Intestinal Clostridium Species: Implications for Clostridium difficile Recurrence (2013) (26)
Comparative in vitro activity of ceftaroline, ceftaroline-avibactam, and other antimicrobial agents against aerobic and anaerobic bacteria cultured from infected diabetic foot wounds. (2013) (26)
Correspondence of In Vitro and In Vivo Fluconazole Dose-Response Curves for Cryptococcus neoformans (2005) (26)
Comparative in vitro activities of amoxicillin-clavulanic acid and imipenem against anaerobic bacteria isolated from community hospitals (1986) (26)
New medium selective for Fusobacterium species and differential for Fusobacterium necrophorum (1981) (26)
ANAEROBIC AND AEROBIC BACTERIOLOGY OF THE SALIVA AND GINGIVA FROM 16 CAPTIVE KOMODO DRAGONS (VARANUS KOMODOENSIS): NEW IMPLICATIONS FOR THE “BACTERIA AS VENOM” MODEL (2013) (26)
Infections following clenched-fist injury: a new perspective. (1978) (26)
Structure-Activity Relationship Studies of a Series of Semisynthetic Lipopeptides Leading to the Discovery of Surotomycin, a Novel Cyclic Lipopeptide Being Developed for the Treatment of Clostridium difficile-Associated Diarrhea. (2015) (25)
Comparative in vitro activities of DU-6859a, levofloxacin, ofloxacin, sparfloxacin, and ciprofloxacin against 387 aerobic and anaerobic bite wound isolates (1997) (25)
Comparison of Etest to broth microdilution method for testing Streptococcus pneumoniae susceptibility to levofloxacin and three macrolides (1996) (25)
Broth Microdilution and Disk Diffusion Tests for Susceptibility Testing of Pasteurella Species Isolated from Human Clinical Specimens (2005) (24)
Effect of inoculum size on in vitro activity of norfloxacin against fecal anaerobic bacteria. Rationale for selective decontamination of the digestive tract. (1987) (24)
The conundrum of the gram-positive rod: are we missing important pathogens in complicated skin and soft-tissue infections? A case report and review of the literature. (2010) (24)
In Vitro Activity of TD-1792, a Multivalent Glycopeptide-Cephalosporin Antibiotic, against 377 Strains of Anaerobic Bacteria and 34 Strains of Corynebacterium Species (2012) (24)
Comparative susceptibilities of 173 aerobic and anaerobic bite wound isolates to sparfloxacin, temafloxacin, clarithromycin, and older agents (1993) (24)
United States National Hospital Survey of anaerobic culture and susceptibility methods, II. (1995) (24)
In Vitro Activities of Telithromycin and 10 Oral Agents against Aerobic and Anaerobic Pathogens Isolated from Antral Puncture Specimens from Patients with Sinusitis (2003) (22)
Difficulty in the identification and differentiation of clinically relevant Ochrobactrum species. (2007) (22)
Characterization of the Bacteroides fragilis pathogenicity island in human blood culture isolates. (2006) (22)
Specimen collection and transport, anaerobic culture techniques, and identification of anaerobes. (1984) (22)
MBX-500, a Hybrid Antibiotic with In Vitro and In Vivo Efficacy against Toxigenic Clostridium difficile (2012) (22)
Fastidious anaerobe agar compared with Wilkins-Chalgren agar, brain heart infusion agar, and brucella agar for susceptibility testing of Fusobacterium species (1990) (21)
In Vitro Activities of ABT-492, a New Fluoroquinolone, against 155 Aerobic and 171 Anaerobic Pathogens Isolated from Antral Sinus Puncture Specimens from Patients with Sinusitis (2003) (21)
In vitro activity of eravacycline and comparator antimicrobials against 143 recent strains of Bacteroides and Parabacteroides species. (2018) (21)
Bacterial counts from five over-the-counter probiotics: are you getting what you paid for? (2014) (21)
Molecular characterization and antimicrobial susceptibilities of extra-intestinal Clostridium difficile isolates. (2007) (21)
16S-23S rRNA gene internal transcribed spacer sequences for analysis of the phylogenetic relationships among species of the genus Porphyromonas. (2005) (20)
Comparative In Vitro Activities of Ertapenem (MK-0826) against 469 Less Frequently Identified Anaerobes Isolated from Human Infections (2002) (20)
Comparative In Vitro Activities of ABT-773 against 362 Clinical Isolates of Anaerobic Bacteria (2001) (20)
Impact of Surotomycin on the Gut Microbiota of Healthy Volunteers in a Phase 1 Clinical Trial (2016) (20)
Comparative In Vitro Activities of GSK2251052, a Novel Boron-Containing Leucyl-tRNA Synthetase Inhibitor, against 916 Anaerobic Organisms (2013) (20)
Activity of a novel carbapenem, doripenem, against anaerobic pathogens. (2009) (19)
In vitro activity of 11 antibiotics against 74 anaerobes isolated from pediatric intra-abdominal infections. (2006) (19)
Comparative In Vitro Activities of Amoxicillin-Clavulanate against Aerobic and Anaerobic Bacteria Isolated from Antral Puncture Specimens from Patients with Sinusitis (1999) (19)
Short prereduced anaerobically sterilized (PRAS) biochemical scheme for identification of clinical isolates of bile-resistant Bacteroides species (1990) (19)
C. difficile infection (CDI) in a long-term acute care facility (LTAC). (2009) (19)
Toxin-producing bacteria in infants. Lack of an association with sudden infant death syndrome. (1981) (19)
Characterization of indole-negative Bacteroides fragilis group species with use of polymerase chain reaction fingerprinting and resistance profiles. (1996) (19)
Impact of prolonged incubation on disk diffusion susceptibility test results for Staphylococcus aureus (1987) (19)
Comparative In Vitro Activities of Relebactam, Imipenem, the Combination of the Two, and Six Comparator Antimicrobial Agents against 432 Strains of Anaerobic Organisms, Including Imipenem-Resistant Strains (2017) (18)
Molecular epidemiology of Clostridioides (Clostridium) difficile strains recovered from clinical trials in the US, Canada and Europe from 2006-2009 to 2012-2015. (2018) (18)
Comparison of Clostridium difficile minimum inhibitory concentrations obtained using agar dilution vs broth microdilution methods. (2017) (18)
Anaerobic identification flowchart using minimal laboratory resources. (1997) (18)
Comparative in vitro activities of ertapenem against bacterial pathogens from patients with acute pelvic infection. (2002) (18)
Cefoxitin for treatment of infections due to anaerobic bacteria. (1979) (17)
Evaluation of Cycloserine-Cefoxitin Fructose Agar (CCFA), CCFA with Horse Blood and Taurocholate, and Cycloserine-Cefoxitin Mannitol Broth with Taurocholate and Lysozyme for Recovery of Clostridium difficile Isolates from Fecal Samples (2013) (17)
Bactericidal Activities of Methoxyfluoroquinolones Gatifloxacin and Moxifloxacin against Aerobic and Anaerobic Respiratory Pathogens in Serum (2003) (17)
Growth characteristics and a novel method for identification (the WEE-TAB system) of Porphyromonas species isolated from infected dog and cat bite wounds in humans (1997) (17)
Activity of ampicillin/sulbactam, ticarcillin/clavulanate, clarithromycin, and eleven other antimicrobial agents against anaerobic bacteria isolated from infections in children. (1995) (16)
Survival of anaerobic bacteria in various thioglycolate and chopped meat broth formulations (1995) (16)
Comparison of the inoculum effect of cefoxitin and other cephalosporins and of beta-lactamase inhibitors and their penicillin-derived components on the Bacteroides fragilis group (1991) (16)
Virulence characteristics of community-associated Staphylococcus aureus and in vitro activities of moxifloxacin alone and in combination against community-associated and healthcare-associated meticillin-resistant and -susceptible S. aureus. (2008) (16)
Ceftaroline versus Isolates from Animal Bite Wounds: Comparative In Vitro Activities against 243 Isolates, Including 156 Pasteurella Species Isolates (2012) (16)
Identification and strain differentiation of 'Bacteroides fragilis group' species and Prevotella bivia by PCR fingerprinting. (1995) (16)
Clostridium difficile Infection Among US Emergency Department Patients With Diarrhea and No Vomiting (2017) (15)
In vitro activity of gemifloxacin compared to seven other oral antimicrobial agents against aerobic and anaerobic pathogens isolated from antral sinus puncture specimens from patients with sinusitis. (2002) (15)
In Vitro Activities of Iodonium Salts against Oral and Dental Anaerobes (2004) (15)
Reproducibility of broth microdilution and comparison to agar dilution for testing CB-183,315 against clinical isolates of Clostridium difficile. (2011) (15)
Differences in distribution and antimicrobial susceptibility of anaerobes isolated from complicated intra-abdominal infections versus diabetic foot infections. (2013) (14)
Comparative in vitro inhibitory and killing activity of cefpirome, ceftazidime, and cefotaxime against Pseudomonas aeruginosa, enterococci, Staphylococcus epidermidis, and methicillin-susceptible and -resistant and tolerant and nontolerant Staphylococcus aureus (1985) (14)
Comparative In Vitro Activity of Omadacycline against Dog and Cat Bite Wound Isolates (2018) (14)
Corrigendum: Description of two novel members of the family Erysipelotrichaceae: Ileibacterium valens gen. nov., sp. nov. and Dubosiella newyorkensis, gen. nov., sp. nov., from the murine intestine, and emendation to the description of Faecalibacterium rodentium. (2017) (14)
Characterization of Bacteroides forsythus Strains from Cat and Dog Bite Wounds in Humans and Comparison with Monkey and Human Oral Strains (1999) (14)
Evaluation of the Velogene Genomic Assay for Detection of vanA and vanB Genes in Vancomycin-Resistant Enterococcus Species (2004) (14)
Methods for testing the susceptibility of anaerobic bacteria to two fluoroquinolone compounds, PD 131628 and clinafloxacin. (1993) (14)
Comparison of the Copan eSwab System with an Agar Swab Transport System for Maintenance of Fastidious Anaerobic Bacterium Viability (2016) (13)
Human serum activity of telithromycin, azithromycin and amoxicillin/clavulanate against common aerobic and anaerobic respiratory pathogens. (2007) (13)
Serum bactericidal activities of moxifloxacin and levofloxacin against aerobic and anaerobic intra-abdominal pathogens. (2008) (12)
Characteristics of Fusobacterium ulcerans, a New and Unusual Species Compared with Fusobacterium varium and Fusobacterium mortiferum (1999) (12)
Rapid Identification of Anaerobes in the Clinical Laboratory (1999) (12)
Genetic Determinant of Intrinsic Quinolone Resistance in Fusobacterium canifelinum (2005) (12)
In Vitro Activities of Garenoxacin (BMS-284756) against 170 Clinical Isolates of Nine Pasteurella Species (2002) (12)
Clostridium innocuum bacteremia secondary to infected hematoma with gas formation in a kidney transplant recipient (2003) (12)
Multilaboratory comparison of growth characteristics for anaerobes, using 5 different agar media. (2002) (11)
Susceptibility of anaerobic bacteria isolated from intra-abdominal infections to ofloxacin and interaction of ofloxacin with metronidazole (1991) (10)
Comparative in-vitro activity of cefoperazone/sulbactam and 11 other agents against multidrug resistant Bacteroides fragilis group species. (1996) (10)
Multilaboratory comparison of anaerobe susceptibility results using 3 different agar media. (2002) (10)
Evaluation of a novel specimen transport system (Venturi Transystem) for anaerobic bacteria. (1997) (10)
Bactericidal activity of telavancin, vancomycin and metronidazole against Clostridium difficile. (2008) (10)
In Vitro Activity of Pexiganan and 10 Comparator Antimicrobials against 234 Isolates, Including 93 Pasteurella Species and 50 Anaerobic Bacterial Isolates Recovered from Animal Bite Wounds (2017) (9)
In Vitro Activities of a New Des-Fluoroquinolone, BMS 284756, and Seven Other Antimicrobial Agents against 151 Isolates of Eikenella corrodens (2002) (9)
Review of the Comparative In vitro Susceptibilities of Lower Female Genital Tract Pathogens to Older and Newer Fluoroquinolones (2000) (9)
Bilophila wadsworthia clinical isolates compared by polymerase chain reaction fingerprinting. (1997) (9)
Pre-molecular identification: ignorance was bliss? (2012) (9)
The underappreciated in vitro activity of tedizolid against Bacteroides fragilis species, including strains resistant to metronidazole and carbapenems. (2017) (8)
Comparative phospholipid analogue distributions of Porphyromonas gingivalis isolated from cats in Australia and the USA. (2001) (8)
Characterization of a beta-lactamase from Clostridium clostridioforme. (1994) (8)
In Vitro Activities of ABT-773, a New Ketolide, against Aerobic and Anaerobic Pathogens Isolated from Antral Sinus Puncture Specimens from Patients with Sinusitis (2001) (7)
Use of polymerase chain reaction fingerprinting to compare clinical isolates of Bacteroides fragilis and Bacteroides thetaiotaomicron from Germany and the United States. (1997) (7)
Bezlotoxumab for the Prevention of Recurrent Clostridioides difficile Infection: 12-Month Observational Data From the Randomized Phase III Trial, MODIFY II. (2019) (7)
Empyema due to Bacteroides gracilis: case report and in vitro susceptibilities to eight antimicrobial agents. (1993) (7)
Mobilization and prevalence of a Fusobacterial plasmid. (2010) (7)
Susceptibility testing of anaerobic bacteria: A review of current methods and future prospects (1992) (6)
PCR fingerprinting analysis for differentiation of Streptococcus pneumoniae reinfection versus relapse. (2000) (6)
Son of anaerobic susceptibility testing— Revisited (1990) (6)
Comparative Activity oftheQuinolones Against Anaerobic Bacteria Isolated atCommunity Hospitals (1985) (6)
Susceptibility testing of anaerobic bacteria. (1983) (6)
Comparative in vitro activity of cefbuperazone against anaerobic bacteria isolated from community hospitals (1985) (5)
In vitro activity of DS-2969b and comparator antimicrobial agents against Clostridioides (Clostridium) difficile, methicillin-resistant Staphylococcus aureus, and other anaerobic bacteria. (2018) (5)
Cefoxitin in the treatment of aerobic and anaerobic infections. Prospective correlation of in vitro susceptibility methods with clinical outcome. (1990) (5)
In Vitro Activity of Tedizolid Compared to Linezolid and Five Other Antimicrobial Agents against 332 Anaerobic Isolates, Including Bacteroides fragilis Group, Prevotella, Porphyromonas, and Veillonella Species (2020) (5)
Characterization of Clostridioides difficile isolates recovered from two Phase 3 surotomycin treatment trials by restriction endonuclease analysis, PCR ribotyping and antimicrobial susceptibilities. (2020) (4)
Disk diffusion antimicrobial-susceptibility testing of the Bacteroides fragilis group using EUCAST clinical minimum inhibitory concentration MIC breakpoints (2013) (4)
Antimicrobial Resistance of Anaerobic Bacteria (2008) (4)
Anti-anaerobic activity of serum from patients treated with tigecycline for skin/soft tissue infections. (2011) (4)
Susceptibility testing of anaerobes--fact, fancy, and wishful thinking. (1989) (4)
Distribution of Fusobacterium Species and Prevalence of Beta-Lactamase Production at a Community Hospital (1999) (4)
Activity of garenoxacin against 536 unusual anaerobes including 128 recovered from acute pelvic infections. (2011) (4)
Immunoblot characterization of Porphyromonas species from infected dog and cat bite wounds in humans. (1997) (3)
In vitro stability of three oral vancomycin preparations stored at 2- 5 °C and ambient room temperature for up to 60 days against 100 Clostridioides (Clostridium) difficile and 51Staphylococcus aureus strains. (2018) (3)
Comparative in vitro activity of imipenem and 15 other antimicrobial agents against clinically important aerobic and anaerobic bacteria. (1988) (3)
Efficacy of bezlotoxumab in trial participants infected with Clostridioides difficile strain BI associated with poor outcomes. (2020) (3)
Escherichia coli resistant to ampicillin/sulbactam. (1992) (3)
Effects of In Vitro Test Method Variables on Ceftaroline Activity Against Aerobic Gram-Positive and -Negative Pathogens (2008) (3)
Serum Bactericidal Activity of Trovafloxacin Against Selected Anaerobic Pathogens (2001) (3)
Sequence conservation and distribution of the fusobacterial immunosuppressive protein gene, fipA. (2002) (3)
anaerobic bite wound isolates. ciprofloxacin against 387 aerobic and levofloxacin, ofloxacin, sparfloxacin, and Comparative in vitro activities of DU-6859a, (2013) (2)
AnnualIncidence, Epidemiology, andComparative InVitro Susceptibilities toCefoxitin, Cefotetan, Cefmetazole, and Ceftizoxime ofRecentCommunity-Acquired Isolates ofthe (1988) (2)
EMERGEncy ID NET: Review of a 20-Year Multisite Emergency Department Emerging Infections Research Network (2017) (2)
In Vitro Activities of Pexiganan and 10 Comparator Antimicrobials against 502 Anaerobic Isolates Recovered from Skin and Skin Structure Infections (2017) (2)
Response to Maja Rupnik. (2016) (1)
Animal Bites (1985) (1)
Introduction and Dedication (2002) (1)
In Vitro Activities of Daptomycin, Vancomycin, Quinupristin- Dalfopristin, Linezolid, and Five Other Antimicrobials against 307 Gram-Positive Anaerobic and 31 Corynebacterium Clinical Isolates (2003) (1)
Comparative in vitro activity of gemifloxacin against aerobic and anaerobic pathogens isolated from antral sinus punctures from patients with sinusitis (2001) (1)
In Vitro Activity of Eravacycline and Comparator Antimicrobials Against 143 Strains of Bacteroides Species. (2017) (1)
Differentiation of clinical Bacteroides ovatus isolates using RNA gene size polymorphisms (1997) (1)
Clinical Efﬁcacy and Correlation of Clinical Outcomes With In Vitro Susceptibility for Anaerobic Bacteria in Patients With Complicated Intra-abdominal Infections Treated With Moxiﬂoxacin (2011) (0)
Characterization of a (Mactamase from Clostridium clostridioforme (1994) (0)
False identification ofNeisseria gonorrhoeae in lower respiratory tract secretions—Result of mixed culture (1979) (0)
Identification and Antimicrobial Resistance Patterns of Clinical Isolates ofClostridium clostridioforme,Clostridium innocuum, andClostridium ramosumCompared with Those of Clinical Isolates ofClostridium perfringens (1995) (0)
Comparative in vitro activity of ciprofloxacin cip ofloxacin ofx ci 960 ci 990 sparfloxacin spx temafloxacin tmx and win 57273 against 293 clinical isolates of anaerobic bacteria (1991) (0)
Decreasing In Vitro Activities of Vancomycin, Metronidazole, and Rifaximin and the REA Types in Contemporary Strains of Clostridium difficile (2008) (0)
Characterization of Bacteroides fragilis group species using PCR fingerprinting and antimicrobial resistance patterns (1996) (0)
Comparative susceptibility of Gemella morbillorum to 13 antimicrobial agents. (2022) (0)
Use of gemifloxacinforbindelser against bacteria (2000) (0)
Leucyl-tRNA Synthetase Inhibitor, against GSK2251052, a Novel Boron-Containing Activities of In Vitro Comparative (2014) (0)
Bacterial Vaginosis Anaerobes Commonly Associated with and Gardnerella vaginalis Sulfate) Inhibit (Polystyrene Sulfonate and Cellulose Two Novel Vaginal Microbicides (2014) (0)
In vitro Activity of Daptomycin, Ciprofloxacin and Other Agents against the Cells and Spores of Clinical Isolates of Bacillus spp. (2005) (0)
Activity of Ceftaroline against Aerobic Gram-Positive and Gram-Negative Pathogens: Effect of Test Method Variability (2011) (0)
Comparative InVitro Activity ofCefbuperazone Against Anaerobic Bacteria Isolated fromCommunity Hospitals (1985) (0)
Characterization of Bacteroides forsythus Strains from Cat and Dog Bite Wounds in Humans and Comparison with Monkey and Human Oral Strains (2000) (0)
Fusobacteria behaving badly: Masquerading strains of strictly anaerobic Escherichia coli misidentified due to the deletion of the hemB gene. (2022) (0)
Bacteriology of Diabetic Foot Infections (DFI): 1640 Isolates from 473 Specimens (2005) (0)
Comparative In Vitro Activities of SMT19969, a New Antimicrobial Agent, against 162 Strains from 35 Less Frequently Recovered Intestinal Clostridium Species: Implications for Clostridium difﬁcile Recurrence (2014) (0)
AUTHOR'S CORRECTION Pelvic Abscess Due to Ochrobactrum anthropi in an Immunocompetent Host: Case Report and Review of the Literature (2007) (0)
ANAEROBIC INFECTION FOLLOWING ANIMAL BITES (1993) (0)
Phospholipid Analogue Profiles of HumanPorphyromonas gingivalisIsolates from Different Geographical Locations (2003) (0)
Impact of Cefoperazone Therapy (0)
The Comparative In Vitro Activity of Ceftobiprole Against 251 Aerobic and 192 Anaerobic Strains Isolated from Diabetic Foot Infections (2006) (0)
Susceptibility ofEikenella corrodens to NewerandOlder Quinolones (1986) (0)
Treatment of Clostridium difficile Infection With Tigecycline: Proof of Concept Study (2013) (0)
National Hospital SurveyofAnaerobic Culture andSusceptibility Testing Methods: Results andRecommendations forImprovement (1992) (0)
292. How Do Komodo Dragons Kill Their Prey?: Lack of Role for Oral Flora in Predation (2012) (0)
1774. Ridinilazole (RDZ) for Clostridium difficile infection (CDI): Correlation of In Vitro Spectrum of Activity with Human Gut Microbiome Profiles from a Phase 2 Clinical Trial (2018) (0)
Phospholipid Analogue Profiles of Human Porphyromonas gingivalis Isolates from Different Geographical Locations (2003) (0)

This paper list is powered by the following services:

What Schools Are Affiliated With Diane M. Citron?

Diane M. Citron is affiliated with the following schools:

University of California, Los Angeles
University of Southern California

Diane M. Citron's Academic­Influence.com Rankings

Why Is Diane M. Citron Influential?

Diane M. Citron's Published Works

Published Works

What Schools Are Affiliated With Diane M. Citron?

Diane M. Citron's AcademicInfluence.com Rankings